Department of Urology, The Netherlands Cancer Institute, Postbus 90203, 1006 BE, Amsterdam, The Netherlands.
Department of Medical Oncology, Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif, France.
Angiogenesis. 2017 May;20(2):205-215. doi: 10.1007/s10456-017-9550-0. Epub 2017 Apr 11.
Antiangiogenic therapy with vascular endothelial growth factor (VEGF) inhibitors is the current first-line treatment in metastatic renal cell carcinoma (mRCC). Immunotherapy with checkpoint inhibitor has been recently added to the armamentarium of mRCC treatment. These therapies are based on treatment with antibodies that block programmed cell death-1 (PD-1), programmed cell death ligand 1 (PD-L1) pathways, demonstrating impressive response rates and improved survival in several tumour types. So far, nivolumab is the only approved anti-PD-1 monoclonal antibody after VEGF therapy in mRCC. According to preclinical and clinical studies, combination therapies with VEGF- and checkpoint inhibitors have synergistic effect achieving improved response rates. However, toxicity in some combinations is high. In this article, we present a review of the ongoing trials with these drug combinations for RCC.
抗血管内皮生长因子（VEGF）抑制剂的血管生成治疗是转移性肾细胞癌（mRCC）的当前一线治疗方法。免疫检查点抑制剂的免疫疗法最近已被添加到 mRCC 治疗方案中。这些疗法基于用抗体阻断程序性细胞死亡-1（PD-1）、程序性细胞死亡配体 1（PD-L1）途径的治疗，在几种肿瘤类型中显示出令人印象深刻的反应率和生存改善。到目前为止，nivolumab 是 mRCC 中 VEGF 治疗后唯一批准的抗 PD-1 单克隆抗体。根据临床前和临床研究，VEGF 和检查点抑制剂的联合治疗具有协同作用，可提高反应率。然而，一些组合的毒性很高。在本文中，我们对这些药物联合用于 RCC 的正在进行的试验进行了综述。
